Q-omics provides the consensus-scored UGT2A1 profile across patient tissues and cancer cell-line models. UGT2A1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, UGT2A1 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, UGT2A1 RNA expression shows 7,183 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, KIRP, and TGCT as cancer lineages where UGT2A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UGT2A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UGT2A1 survival associations across molecular data types. UGT2A1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UGT2A1 RNA expression–survival associations across cancer types. High UGT2A1 expression shows unfavorable associations in ACC and LIHC, but favorable associations in SCLC, LUAD, BLCA and CESC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for UGT2A1 RNA expression.
This table summarizes UGT2A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UGT2A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UGT2A1 shows lower tumor expression in KIRP, KIRC, KICH, CHOL and LIHC and higher tumor expression in LUSC. The KIRP box plot shows higher UGT2A1 RNA expression in normal versus tumor tissue (log2 FC = −1.711, t-test p < 0.001).
This table shows molecular features associated with UGT2A1 in patient tissues and cancer cell lines. In patient samples, UGT2A1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UGT2A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
